Forskning ved Københavns Universitet - Københavns Universitet

Forside

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. / Herukka, Sanna-Kaisa; Simonsen, Anja Hviid; Andreasen, Niels; Baldeiras, Ines; Bjerke, Maria; Blennow, Kaj; Engelborghs, Sebastiaan; Frisoni, Giovanni B; Gabryelewicz, Tomasz; Galluzzi, Samantha; Handels, Ron; Kramberger, Milica G; Kulczyńska, Agnieszka; Molinuevo, Jose Luis; Mroczko, Barbara; Nordberg, Agneta; Oliveira, Catarina Resende; Otto, Markus; Rinne, Juha O; Rot, Uroš; Saka, Esen; Soininen, Hilkka; Struyfs, Hanne; Suardi, Silvia; Visser, Pieter Jelle; Winblad, Bengt; Zetterberg, Henrik; Waldemar, Gunhild.

I: Alzheimer's & Dementia, Bind 13, Nr. 3, 03.2017, s. 285-295.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Herukka, S-K, Simonsen, AH, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczyńska, A, Molinuevo, JL, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment', Alzheimer's & Dementia, bind 13, nr. 3, s. 285-295. https://doi.org/10.1016/j.jalz.2016.09.009

APA

Herukka, S-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., ... Waldemar, G. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia, 13(3), 285-295. https://doi.org/10.1016/j.jalz.2016.09.009

Vancouver

Herukka S-K, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K o.a. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia. 2017 mar;13(3):285-295. https://doi.org/10.1016/j.jalz.2016.09.009

Author

Herukka, Sanna-Kaisa ; Simonsen, Anja Hviid ; Andreasen, Niels ; Baldeiras, Ines ; Bjerke, Maria ; Blennow, Kaj ; Engelborghs, Sebastiaan ; Frisoni, Giovanni B ; Gabryelewicz, Tomasz ; Galluzzi, Samantha ; Handels, Ron ; Kramberger, Milica G ; Kulczyńska, Agnieszka ; Molinuevo, Jose Luis ; Mroczko, Barbara ; Nordberg, Agneta ; Oliveira, Catarina Resende ; Otto, Markus ; Rinne, Juha O ; Rot, Uroš ; Saka, Esen ; Soininen, Hilkka ; Struyfs, Hanne ; Suardi, Silvia ; Visser, Pieter Jelle ; Winblad, Bengt ; Zetterberg, Henrik ; Waldemar, Gunhild. / Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. I: Alzheimer's & Dementia. 2017 ; Bind 13, Nr. 3. s. 285-295.

Bibtex

@article{bbd3f8f508eb4853b534d2cb9b02fb25,
title = "Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment",
abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.",
keywords = "Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Cognitive Dysfunction, Humans, MEDLINE, Peptide Fragments, tau Proteins, Journal Article, Review",
author = "Sanna-Kaisa Herukka and Simonsen, {Anja Hviid} and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G} and Agnieszka Kulczyńska and Molinuevo, {Jose Luis} and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O} and Uroš Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",
note = "Copyright {\circledC} 2016 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = "3",
doi = "10.1016/j.jalz.2016.09.009",
language = "English",
volume = "13",
pages = "285--295",
journal = "Alzheimer's & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

AU - Herukka, Sanna-Kaisa

AU - Simonsen, Anja Hviid

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G

AU - Kulczyńska, Agnieszka

AU - Molinuevo, Jose Luis

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O

AU - Rot, Uroš

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

N1 - Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2017/3

Y1 - 2017/3

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

KW - Alzheimer Disease

KW - Amyloid beta-Peptides

KW - Biomarkers

KW - Cognitive Dysfunction

KW - Humans

KW - MEDLINE

KW - Peptide Fragments

KW - tau Proteins

KW - Journal Article

KW - Review

U2 - 10.1016/j.jalz.2016.09.009

DO - 10.1016/j.jalz.2016.09.009

M3 - Journal article

C2 - 28341066

VL - 13

SP - 285

EP - 295

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5260

IS - 3

ER -

ID: 186323977